Home » Clinical Trials »  Search Clinical Trials

Therapeutic Areas:  |  Oncology  |  Family Medicine

Search Medical Condition
Please enter condition
Please choose location from dropdown
Clear Trial Filters

Adenocarcinoma Clinical Trials

A listing of Adenocarcinoma medical research trials actively recruiting patient volunteers. Search for closest city to find more detailed information on a research study in your area.

RESULTS

Found (81) clinical trials

Fluciclovine-PET/CT for Bone Metastases From Prostate Adenocarcinoma

Determine diagnostic accuracy of Axumin-PET positive bone lesion by confirmatory bone biopsy.

Phase N/A

Hypofractionated Stereotactic Body Radiation Therapy for Patients With Prostate Cancer That Was Removed by Surgery

PRIMARY OBJECTIVES: I. To determine maximum tolerated dose-per-fraction for SBRT to the prostate fossa following prostatectomy based on acute toxicity (< 90 days). SECONDARY OBJECTIVES: I. To describe the acute (< 90 days) toxicities and adverse events associated with hypofractionated SBRT when administered to the prostate bed in the post-prostatectomy ...

Phase N/A

Efficacy and Safety Assessment of IRE of Localized Prostate Cancer.

Irreversible electroporation is a newly developed non-thermal tissue ablation technique in which short duration electrical fields are used to form permanent nanoscale defects in the cell membrane which leads to cell apoptosis. Thus, IRE is a non-thermal technique, which means that changes associated with tissue freezing or heating are not ...

Phase N/A

68Ga-RM2 PET/MRI in Biochemically Recurrent Prostate Cancer

PRIMARY OBJECTIVES: I. To evaluate 68Ga-RM2 (formerly known as DOTA bombesin or BAY 86-7548) PET/MRI for detection of recurrent prostate cancer after initial therapy in patients with elevated prostate-specific antigen (PSA) and non-contributory computed tomography (CT). OUTLINE Patients receive 68Ga-RM2 intravenously (IV) and beginning 45 minutes later undergoing PET/MRI scan. ...

Phase

Enzalutamide Versus Standard Androgen Deprivation Therapy for the Treatment Hormone Sensitive Prostate Cancer

PRIMARY OBJECTIVES: I. To determine the incidence of metabolic syndrome within 12 months, as defined by the Adult Treatment Panel III, in patients treated with enzalutamide compared to standard androgen deprivation therapy. SECONDARY OBJECTIVES: I. To determine the incidence of metabolic syndrome within 6 months, as defined by the Adult ...

Phase

Phase 1/2A Study of TRC253 an Androgen Receptor Antagonist in Metastatic Castration-resistant Prostate Cancer Patients

The patient population consists of men 18 years of age with adenocarcinoma of the prostate with metastatic disease. Patients who have not undergone orchiectomy must have serum testosterone levels <50 ng/dL determined within 4 weeks prior to start of study drug, and, if applicable, must have discontinued treatment with first ...

Phase

Single Arm Study of 6-Months Neoadjuvant ARN-509 Prior to Radical Prostatectomy

Study Drug Administration: If you are found to be eligible to take part in the study, you will take 4 tablets of apalutamide by mouth each day for a total of 24 weeks (about 6 months) leading up to your standard-of-care prostate surgery. You should take apalutamide at about the ...

Phase

Molecular PET/MR Imaging in Vivo Validation of Biomarker for Human Prostate Cancer

According to 2015 National Comprehensive Cancer Network (NCCN) guideline, medical imaging plays important roles for detection and staging for PCa, in addition to blood or urine biomarkers. Although there are a number of very different diagnostic imaging methods, e.g. transrectal ultrasound (TRUS), computed tomography (CT), magnetic resonance (MR) imaging and ...

Phase N/A

ESK981 in Treating Patients With Metastatic Castrate-Resistant Prostate Cancer

PRIMARY OBJECTIVES: I. To determine the PSA >= 50% response rate (PSA50) from baseline using the Prostate Cancer Working Group 3 (PCWG3) criteria to pan-VEGFR/TIE2 tyrosine kinase inhibitor CEP-11981 (ESK981) as a single agent in men with castration-resistant prostate cancer (CRPC) who have progressed on enzalutamide (an oral androgen-receptor inhibitor) ...

Phase

Apalutamide in Treating Patients With Prostate Cancer Who Are in Active Surveillance

PRIMARY OBJECTIVES: I. Determine the negative repeat biopsy rate by site directed and systematic prostate biopsy after 90-days of apalutamide. SECONDARY OBJECTIVES: I. Determine the rate of exit at 2 years from active surveillance due to pathologic reclassification. II. Determine the overall rate of exit at 2 years from active ...

Phase